Target
Placebo
27 abstracts
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial.Org: Sysmex Inostics Gmbh, Sysmex Inostics, Inc., GEICAM Spanish Breast Cancer Group, Cancer Trials Ireland, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) ,
Abstract
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.Org: Bristol Myers Squibb, Oncosite Centro de Pesquisa Clínica em Oncologia, Puerta de Hierro University Hospital, Madrid, Spain, Dana-Farber Cancer Institute, Boston, MA, USA, McGill University Health Centre, Montreal, QC, Canada,
Abstract
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.Org: Mayo Clinic Department of Radiation Oncology, Rochester, MN, Mayo Clinic, Phoenix, AZ, Division of Hematology & Medical Oncology,
Abstract
On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).Org: BC Cancer - Vancouver Centre, Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori Regina Elena,
Abstract
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.Org: Hospital del Mar, Barcelona, Spain, CIBERONC-ISCIII, Biovica International AB, Hospital Clínico Universitario de Valencia, INCLIVA-Biomedical Research Institute,
Abstract
Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.Org: AMITA Health Adventist Medical Center, Indiana University Health & Simon Cancer Center, Hungarian National Institute of Oncology, Soroka University Medical Center, OLV Hospital,
Abstract
Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.Org: Divisions of Medical Oncology and Urology, Bayer Consumer Care AG,
Abstract
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.Org: Maria Sklodowska-Curie National Cancer Research Institute,
Abstract
Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.Org: Stamford, CT,
Abstract
Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC).Org: Amsterdam UMC, University of Amsterdam, ENETS Center of Excellence, Cancer Center Amsterdam, Charite Campus Charite Mitte,
Abstract
Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.Org: Yale University, Azienda Ospedaliero Universitaria Careggi, University of Florence, University of Florence, AOUC, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, University Hospital Leipzig,
Abstract
Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).Org: Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Prince of Wales Hospital, Department of Clinical Oncology, The Chinese University of Hong Kong, Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, ENETS Center of Excellence, Cancer Center Amsterdam, Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Department, Hannover Medical School,
Abstract
Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.Org: GOG Foundation, National Cancer Center Korea, Hospital Universitario Virgen de Valme, Department of Cancer and Blood, Limited Liability Company MedPomosch,
Abstract
Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.Org: Department of Oncology, Odense University Hospital, Willis-Knighton Cancer Center, Gynecologic Oncology Associates, Department of Gynaecology, Obstetrics, and Neonatology, General University Hospital in Prague, Division of Gynecologic Oncology, McGill University Health Centre,
Abstract
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.Org: Veneto Institute of Oncology IOV-IRCCS Padua, Asklepios Tumorzentrum Hamburg, Takeda Pharma Vertrieb GmbH & Co. KG, HUTCHMED International Inc., University Hospitals Gasthuisberg / Leuven & KULeuven,
Abstract
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,
Abstract
Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.Org: All India Institute of Medical Sciences, Dr. Brairch, Abbisko Therapeutics, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, All India Institute of Medical Science (AIIMS),
Abstract
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.Org: Institut Gustave Roussy, Hospital Universitario y Politecnico La Fe, ICO-Hospital Germans Trias i Pujol, Medical University of Gdansk, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.Org: The University of Arizona, Tucson, AZ, University of Arizona Cancer Center, University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,
Abstract
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.Org: North Estonia Medical Centre Foundation, The Catholic University of Korea, Hiroshima University Hospital, Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,
Abstract
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.Org: Kliniken Essen-Mitte, Agomab Spain, Centre Jean Perrin, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Istituto Tumori Milano + Fondazione Policlinico Universitario A. Gemelli IRCCS,
Abstract
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.Org: IQVIA Inc., Bratislava, Slovakia, IQVIA, Amsterdam, Netherlands, SpringWorks Therapeutics, Universität Heidelberg, Mannheim Cancer Center (MCC),
Abstract
Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.Org: Qilu Hospital of Shandong University, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI).Org: University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, University of Rochester Medical School, AdventHealth Orlando,
Abstract
Prevention of chemotherapy-induced neutropenia (CIN) with plinabulin (Plin) vs placebo (Plac) in patients (pts) with non-small cell lung cancer (NSCLC) treated with docetaxel (Doc): A pooled analysis from 3 randomized trials.Org: Stanford Cancer Institute, Stanford, CA, BeyondSpring Pharmaceuticals, Inc., New York, NY, Newyork, NY,
Abstract
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.Org: APHP-INSERM U1149 Universite Paris Diderot, European Georges Pompidou Hospital, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université,